Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1478, 2005-01, pp. : 19-19
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Docetaxel + carboplatin has the edge for advanced NSCLC
Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. :
Access to resources
Recommend
Docetaxel plus cisplatin: active and well tolerated in locally advanced or metastatic gastric cancer
Inpharma, Vol. 1, Iss. 1278, 2001-01 ,pp. :
S-1 + cisplatin promising for advanced NSCLC
Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. :
Cisplatin + pemetrexed as first-line therapy for advanced NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. :
Docetaxel plus gemcitabine shows antitumour efficacy in patients with advanced NSCLC
Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. :